• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

线粒体疾病研究重点:当前状况及患者和专业人员观点。

Research priorities for mitochondrial disorders: Current landscape and patient and professional views.

机构信息

Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.

Genetic Alliance UK, London, UK.

出版信息

J Inherit Metab Dis. 2022 Jul;45(4):796-803. doi: 10.1002/jimd.12521. Epub 2022 May 31.

DOI:10.1002/jimd.12521
PMID:35543492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9429991/
Abstract

Primary mitochondrial disorders encompass a wide range of clinical presentations and a spectrum of severity. They currently lack effective disease-modifying therapies and have a high mortality and morbidity rate. It is therefore essential to know that competitively funded research designed by academics meets the core needs of people with mitochondrial disorders and their clinicians. Priority setting partnerships are an established collaborative methodology that brings patients, carers and families, charity representatives and clinicians together to try to establish the most pressing and unanswered research priorities for a particular disease. We developed a web-based questionnaire, requesting all patients affected by primary mitochondrial disease, their carers and clinicians to pose their research questions. This yielded 709 questions from 147 participants. These were grouped into overarching themes including basic biology, causation, health services, clinical management, social impacts, prognosis, prevention, symptoms, treatment and psychological impact. Following the removal of "answered questions", the process resulted in a list of 42 discrete, answerable questions. This was further refined by web-based ranking by the community to 24 questions. These were debated at a face-to-face workshop attended by a diverse range of patients, carers, charity representatives and clinicians to create a definitive "Top 10 of unanswered research questions for primary mitochondrial disorders". These Top 10 questions related to understanding biological processes, including triggers of disease onset, mechanisms underlying progression and reasons for differential symptoms between individuals with identical genetic mutations; new treatments; biomarker discovery; psychological support and optimal management of stroke-like episodes and fatigue.

摘要

原发性线粒体疾病包括广泛的临床表现和严重程度范围。它们目前缺乏有效的疾病修饰疗法,死亡率和发病率都很高。因此,必须知道由学者设计的有竞争力的资助研究满足了线粒体疾病患者及其临床医生的核心需求。优先设定伙伴关系是一种既定的协作方法,它将患者、照顾者和家属、慈善代表和临床医生聚集在一起,试图确定特定疾病最紧迫和未得到解答的研究优先事项。我们开发了一个基于网络的问卷,要求所有受原发性线粒体疾病影响的患者、他们的照顾者和临床医生提出他们的研究问题。这从 147 名参与者中产生了 709 个问题。这些问题被分为包括基础生物学、病因、卫生服务、临床管理、社会影响、预后、预防、症状、治疗和心理影响在内的总体主题。在删除“已回答的问题”后,该过程产生了 42 个离散的、可回答的问题列表。通过社区的在线排名进一步将其细化为 24 个问题。这些问题在一次面对面的研讨会上进行了辩论,参加者包括来自不同背景的患者、照顾者、慈善代表和临床医生,以确定原发性线粒体疾病“未解答研究问题的前 10 名”。这前 10 个问题涉及对生物过程的理解,包括疾病发作的触发因素、进展背后的机制以及个体之间相同基因突变导致的不同症状的原因;新的治疗方法;生物标志物发现;心理支持和中风样发作和疲劳的最佳管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106e/9429991/ff76cd92b511/JIMD-45-796-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106e/9429991/ff76cd92b511/JIMD-45-796-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106e/9429991/ff76cd92b511/JIMD-45-796-g001.jpg

相似文献

1
Research priorities for mitochondrial disorders: Current landscape and patient and professional views.线粒体疾病研究重点:当前状况及患者和专业人员观点。
J Inherit Metab Dis. 2022 Jul;45(4):796-803. doi: 10.1002/jimd.12521. Epub 2022 May 31.
2
Identifying research priorities in cardiac surgery: a report from the James Lind Alliance Priority Setting Partnership in adult heart surgery.确定心脏外科学术研究重点:成人心脏外科学术重点制定合作研究组的报告。
BMJ Open. 2020 Sep 3;10(9):e038001. doi: 10.1136/bmjopen-2020-038001.
3
Setting research priorities to improve the health of children and young people with neurodisability: a British Academy of Childhood Disability-James Lind Alliance Research Priority Setting Partnership.确定研究重点,以改善患有神经残疾的儿童和年轻人的健康:英国儿童残疾学会-詹姆斯·林德联盟研究重点制定伙伴关系。
BMJ Open. 2015 Jan 28;5(1):e006233. doi: 10.1136/bmjopen-2014-006233.
4
Research priorities for the management of complex fractures: a UK priority setting partnership with the James Lind Alliance.复杂骨折管理的研究重点:英国与詹姆斯·林德联盟的优先事项设定伙伴关系。
BMJ Open. 2021 Nov 30;11(11):e057198. doi: 10.1136/bmjopen-2021-057198.
5
Research priorities in advanced heart failure: James Lind alliance priority setting partnership.晚期心力衰竭的研究重点:詹姆斯·林德联盟优先事项设定合作项目
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001258.
6
Research priorities in pernicious anaemia: James Lind Alliance Priority Setting Partnership.恶性贫血研究重点:詹姆斯·林德联盟优先事项设定伙伴关系。
BMJ Open. 2022 Aug 24;12(8):e065166. doi: 10.1136/bmjopen-2022-065166.
7
Research priorities to improve the health of children and adults with dysphagia: a National Institute of Health Research and Royal College of Speech and Language Therapists research priority setting partnership.改善吞咽障碍儿童和成人健康的研究重点:英国国家卫生研究院和皇家言语治疗师学院的研究重点制定伙伴关系。
BMJ Open. 2022 Jan 25;12(1):e049459. doi: 10.1136/bmjopen-2021-049459.
8
Identifying and prioritising unanswered research questions for people with hyperacusis: James Lind Alliance Hyperacusis Priority Setting Partnership.确定和优先考虑患有听觉过敏症人群的未解决研究问题:詹姆斯林德联盟听觉过敏优先事项设定伙伴关系。
BMJ Open. 2019 Nov 21;9(11):e032178. doi: 10.1136/bmjopen-2019-032178.
9
Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership.转移性乳腺癌研究重点:詹姆斯·林德联盟优先事项设定伙伴关系。
Breast J. 2020 Mar;26(3):488-493. doi: 10.1111/tbj.13525. Epub 2019 Sep 2.
10
Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership.常染色体显性遗传性多囊肾病研究重点:英国优先事项设定伙伴关系。
BMJ Open. 2022 Jun 15;12(6):e055780. doi: 10.1136/bmjopen-2021-055780.

引用本文的文献

1
Development of the Dutch translational knowledge agenda for inherited metabolic diseases.荷兰遗传性代谢疾病转化知识议程的制定。
JIMD Rep. 2024 Dec 22;66(1):e12455. doi: 10.1002/jmd2.12455. eCollection 2025 Jan.
2
Emerging Multi-omic Approaches to the Molecular Diagnosis of Mitochondrial Disease and Available Strategies for Treatment and Prevention.线粒体疾病分子诊断的新兴多组学方法及可用的治疗与预防策略
Curr Genomics. 2024;25(5):358-379. doi: 10.2174/0113892029308327240612110334. Epub 2024 Jun 14.
3
Towards values-based healthcare for inherited metabolic disorders: An overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders.

本文引用的文献

1
Forecasting stroke-like episodes and outcomes in mitochondrial disease.预测线粒体疾病中的中风样发作和结局。
Brain. 2022 Apr 18;145(2):542-554. doi: 10.1093/brain/awab353.
2
Adeno-associated viral vector serotype 9-based gene replacement therapy for -related Leigh syndrome.基于9型腺相关病毒载体的基因替代疗法治疗与[具体疾病]相关的Leigh综合征。 (你提供的原文中“-related”前缺失了疾病相关信息)
Mol Ther Methods Clin Dev. 2021 Sep 7;23:158-168. doi: 10.1016/j.omtm.2021.09.001. eCollection 2021 Dec 10.
3
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.
迈向基于价值观的遗传性代谢疾病医疗保健:肝糖贮积症和脂肪酸氧化障碍患者现行实践概述。
J Inherit Metab Dis. 2022 Nov;45(6):1018-1027. doi: 10.1002/jimd.12555. Epub 2022 Sep 30.
4
The immune system as a driver of mitochondrial disease pathogenesis: a review of evidence.免疫系统作为线粒体疾病发病机制的驱动因素:证据综述。
Orphanet J Rare Dis. 2022 Sep 2;17(1):335. doi: 10.1186/s13023-022-02495-3.
单侧基因治疗注射治疗莱伯遗传性视神经病变的双侧视力改善。
Sci Transl Med. 2020 Dec 9;12(573). doi: 10.1126/scitranslmed.aaz7423.
4
Seeking impact: Global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders.寻求影响:原发性线粒体疾病转化和临床研究中结局测量选择的全球观点。
J Inherit Metab Dis. 2021 Mar;44(2):343-357. doi: 10.1002/jimd.12320. Epub 2020 Oct 29.
5
The impact of gender, puberty, and pregnancy in patients with POLG disease.POLG 病患者的性别、青春期和妊娠的影响。
Ann Clin Transl Neurol. 2020 Oct;7(10):2019-2025. doi: 10.1002/acn3.51199. Epub 2020 Sep 18.
6
A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing.一种细菌胞嘧啶脱氨酶毒素可实现无 CRISPR 的线粒体碱基编辑。
Nature. 2020 Jul;583(7817):631-637. doi: 10.1038/s41586-020-2477-4. Epub 2020 Jul 8.
7
Moving towards clinical trials for mitochondrial diseases.迈向线粒体疾病临床试验。
J Inherit Metab Dis. 2021 Jan;44(1):22-41. doi: 10.1002/jimd.12281. Epub 2020 Sep 2.
8
Mitochondrial Diseases: Hope for the Future.线粒体疾病:未来的希望。
Cell. 2020 Apr 2;181(1):168-188. doi: 10.1016/j.cell.2020.02.051. Epub 2020 Mar 26.
9
Mitochondrial disease in children.儿童线粒体疾病。
J Intern Med. 2020 Jun;287(6):609-633. doi: 10.1111/joim.13054. Epub 2020 Apr 7.
10
Strategies for fighting mitochondrial diseases.对抗线粒体疾病的策略。
J Intern Med. 2020 Jun;287(6):665-684. doi: 10.1111/joim.13046. Epub 2020 Apr 13.